Implantation of a carotid artery stent, used with an embolic protection device, intended as an alternative to carotid endarterectomy for patients with severe carotid artery stenosis at average to low risk of surgical complications.
Horizon Scanning
It is a challenge for health plans and clinicians to know what emerging technologies are in the preapproval phase and what their clinical, financial, and risk impacts might be. This is where we come in.The Hayes Horizon Scanning Solution identifies innovative and potentially disruptive health technologies that are in various stages of the regulatory approval process. Our Research Analysts continually investigate new technologies that are on the horizon or in the early stages of clinical investigation, as well as the testing of existing technologies that may be seeking approval for new clinical applications. Hayes Horizon Scanning helps you track emerging technologies before you need to make decisions. Accessed through the Hayes Knowledge Center, Hayes Horizon Scanning addresses the following fundamental questions to help our clients forecast emerging technologies:
- Is this emerging technology new or replacing an existing technology?
- Where is this technology in the FDA regulatory process?
- When will this technology be commercially available in the market?
- What is the projected use, cost, and financial impact of this technology?
TOGA® System (Transoral Gastroplasty)
An endoluminal stomach stapling device used in an incisionless restrictive procedure to treat morbid obesity.
Zytiga™ (Abiraterone Acetate)
A first-in-class oral CYP17 inhibitor proposed initially for use in combination with prednisone to treat metastatic castration-resistant prostate cancer (CRPC) in patients previously treated with a docetaxel chemotherapy.
Actemra® (Tocilizumab) for Juvenile Idiopathic Arthritis
An intravenous monoclonal antibody to the interleukin-6 receptor, proposed for the second- or third-line treatment of children with juvenile idiopathic arthritis.
Vernakalant (Proposed Name, US: Kynapid™; Brinavess™ [Europe])
An intravenous antiarrhythmic for the conversion of recent onset atrial fibrillation to sinus rhythm.
Fingolimod (Gilenya™)
An oral immunomodulating agent for the treatment of relapsing-remitting multiple sclerosis.
Dimebon™ (Dimebolin Hydrochloride)
An orally available, small molecule being developed as a potential treatment for mild-to-moderate Alzheimer’s disease.
Benlysta® (Belimumab)
Intravenous infusion to treat seropositive systemic lupus erythematosus in combination with standard therapy.
AMPLIFY™ Recombinant Human Bone Morphogenetic Protein (rhBMP-2) Matrix
A recombinant human bone morphogenetic protein (rhBMP-2) with a compression-resistant matrix intended for posterolateral lumbar spinal fusion in patients with symptomatic, single-level degenerative disc disease.
Optical Coherence Tomography (OCT) for Multiple Sclerosis
A noninvasive imaging technology for retinal assessment being developed as an alternative to magnetic resonance imaging for the monitoring of progression of multiple sclerosis.